A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss.
Santini
D
D
Oncology, University Campus Bio-Medico, Via Emilio Longoni 69, 00155 Rome. Electronic address: d.santini@unicampus.it.
Vincenzi
B
B
Oncology, University Campus Bio-Medico, Via Emilio Longoni 69, 00155 Rome.
Caraglia
M
M
Experimental Oncology Department, Experimental Pharmacology Unit, National Cancer Institute Fondazione 'G. Pascale', Naples, Italy.
Tonini
G
G
Oncology, University Campus Bio-Medico, Via Emilio Longoni 69, 00155 Rome.
D000210:Acute-Phase Reaction / Q000209:etiology*; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D015994:Incidence; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy*; D000077211:Zoledronic Acid
D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid